A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System
Dongdong Zhang, Ying Cai, Yixin Sun, Peiji Zeng, Wei Wang, Wenhui Wang, Xiaohua Jiang, Yifan Lian · 2024
Read A real-world pharmacovigilance study of Sorafenib based on the FDA Adverse Event Reporting System by Dongdong Zhang, Ying Cai, Yixin Sun, Peiji Zeng, Wei Wang, Wenhui Wang, Xiaohua Jiang, Yifan Lian (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11685139.txt.
Description
Dongdong Zhang and seven co-authors mine United States drug safety reports for side effects of a cancer drug, in a 2024 study. The drug, sorafenib, treats liver, kidney, and thyroid cancers. Reports spanned twenty years of the federal database. The team used signal math to spot effects that show up more often than chance would predict.
More than eighteen thousand patients and eighty thousand effects were logged. Known effects such as diarrhea, hand-foot skin pain, fatigue, and rash matched the drug label. Fresh signals also stood out, among them loss of walking ability and thickened palm skin. The authors urge steady watch for these unlisted effects in clinic use.
Catalog record
| CREATOR | Dongdong Zhang, Ying Cai, Yixin Sun, Peiji Zeng, Wei Wang, Wenhui Wang, Xiaohua Jiang, Yifan Lian |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |